Information Provided By:
Fly News Breaks for November 24, 2015
ZION, WIX, WFC, USCR, USB, SBOT, STI, STLD, POWR, ORCL, PNC, NUE, MRK, INAP, HBAN, GVA, EQIX, FITB, DFT, CONE, COYN, CFG, BBT
Nov 24, 2015 | 10:00 EDT
Today's noteworthy initiations include: BB&T (BBT) initiated with a Neutral at Piper Jaffray... Citizens Financial (CFG) initiated with an Overweight at Piper Jaffray... Copsync (COYN) initiated with a Buy at Maxim... CyrusOne (CONE) initiated with a Buy at SunTrust... DuPont Fabros (DFT) initiated with a Buy at SunTrust... Equinix (EQIX) initiated with a Buy at SunTrust... Fifth Third (FITB) initiated with a Neutral at Piper Jaffray... Granite Construction (GVA) initiated with a Buy at Maxim... Huntington Bancshares (HBAN) initiated with a Neutral at Piper Jaffray... Internap (INAP) initiated with a Neutral at SunTrust... KeyCorp (KEY) initiated with an Overweight at Piper Jaffray... Merck (MRK) initiated with a Hold at Berenberg... Nucor (NUE) initiated with a Buy at BB&T... Oracle (ORCL) initiated with a Buy at SunTrust... PNC Financial (PNC) initiated with an Overweight at Piper Jaffray... PowerSecure (POWR) initiated with a Buy at Canaccord... Regions Financial (RF) initiated with a Neutral at Piper Jaffray... Steel Dynamics (STLD) initiated with a Buy at BB&T... Stellar Biotechnologies (SBOT) initiated with a Buy at Maxim... SunTrust (STI) initiated with an Overweight at Piper Jaffray... Teladoc (TDOC) initiated with an Outperform at Oppenheimer... U.S. Bancorp (USB) initiated with an Overweight at Piper Jaffray... U.S. Concrete (USCR) initiated with a Buy at Sidoti... Wells Fargo (WFC) initiated with a Neutral at Piper Jaffray... Wix.com (WIX) initiated with an Outperform at JMP Securities... Zions Bancorp (ZION) initiated with a Neutral at Piper Jaffray.
News For BBT;CFG;COYN;CONE;DFT;FITB;EQIX;GVA;HBAN;INAP;MRK;NUE;PNC;ORCL;POWR;STLD;STI;SBOT;USB;USCR;WFC;WIX;ZION From the Last 2 Days
MRK
Mar 28, 2024 | 06:48 EDT
Merck announced that the European Commission has approved Keytruda, Merck's anti-PD-1 therapy, in combination with platinum-containing chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for resectable non-small cell lung cancer at high risk of recurrence in adults.
MRK
Mar 27, 2024 | 16:24 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
MRK
Mar 27, 2024 | 12:00 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.  1... To see the rest of the story go to thefly.com. See Story Here
MRK
Mar 27, 2024 | 08:55 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly.  HIGHER - Robinhood (HOOD)... To see the rest of the story go to thefly.com. See Story Here
MRK
Mar 27, 2024 | 07:19 EDT
BofA notes that Merck shares have been volatile as investors have contemplated various scenarios regarding the approval of sotatercept and its language, including "a lot of investor angst" given the risk for the FDA to issue either black box warnings, REMS, and/or monitoring requirement. However, sotatercept's approval in PAH with the brand name Winrevair "comes with a squeaky-clean label," without WHO functional class restriction or a need to be on background therapy, no black box and no REMS, which represents "the most bullish scenario," the analyst tells investors. The firm, which anticipates Merck shares to react favorably, maintains a Buy rating and $135 price target and sees upside to sotatercept's commercial outlook.
MRK
Mar 27, 2024 | 06:12 EDT
Wells Fargo raised the firm's price target on Merck to $135 from $130 and keeps an Equal Weight rating on the shares. The firm notes WINREVAIR, or sotatercept, was approved with simple monitoring on the label, removing an overhang on the stock. $242k annual pricing is competitive and could enable the drug to move into earlier lines, and Wells now models $7B peak sales opportunity.